Furthermore, Chuang et al. (2021) [55] evaluated the effects of two additional PI3K inhibitors, Alpelisib (BYL719) and Buparlisib (BKM120), and observed a marked reduction in tumor cell growth. This evidence concerns the gene PIK3CA and neoplasm.